Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets – European Huntington Association

Prilenia has entered into a significant collaboration with Ferrer to commercialize and further develop pridopidine in Europe and select markets. Pridopidine is a potent and highly selective  orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD.